Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.Founded in 2018 by lead metagenomics researchers at UC Berkeley, Brian C. Thomas and Jillian Banfield, Metagenomi is committed to changing the landscape of cell and gene therapies. By using metagenomics to unlock 4 billion years of microbial evolution, Metagenomi is rapidly identifying and characterizing novel nucleases with unique gene editing capabilities. Metagenomi is using this expanded gene editing toolbox to develop game-changing in vivo and ex vivo therapeutics.
B2B
26 to 50
Series A
$65,000,000
Scaling Up
2018
Biotechnology
N/A
Microbial Innovations
Analytics
Service
Yes
Active
Machine Learning
Machine Perception
Software
N/A
AI/ML Professionals
Want to work at Metagenomi?
We can introduce you to the right person at Metagenomi
0
1
$100M
Company was founded 2018 and it took almost 5 years (Jan 2023) to raise first external round
Investors
Interested in researching Metagenomi?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Metagenomi
Potential Customers
Interested in what they do or partnership?
Learn more about how they work